Human C3a(Complement Component 3a) ELISA Kit (E-EL-H0818)

This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human C3a. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human C3a and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human C3a, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human C3a. You can calculate the concentration of Human C3a in the samples by comparing the OD of the samples to the standard curve.

Human complement component 3a (C3a) is a small anaphylatoxin peptide of about 9 kDa generated by proteolytic cleavage of complement component C3. C3 is the central protein of the complement cascade and is cleaved by the C3 convertases of the classical, lectin and alternative pathways, releasing the soluble fragment C3a while the large fragment C3b becomes covalently attached to target surfaces. C3a binds the G-protein-coupled C3a receptor on mast cells, granulocytes and endothelial cells, triggering calcium mobilization, mast-cell degranulation, leukocyte chemotaxis and increased vascular permeability, thereby amplifying the local inflammatory response. The peptide also displays direct antimicrobial activity against susceptible bacteria. Removal of its C-terminal arginine by serum carboxypeptidase N generates the des-arginine form with greatly reduced activity, limiting the duration of the signal. Generation of C3a is an early and sensitive indicator of complement activation in infection, ischemia-reperfusion injury, sepsis and autoimmune disease, and C3 gene variants are associated with atypical hemolytic uremic syndrome. This ELISA kit enables quantitative determination of C3a in serum, plasma and other biological samples, allowing assessment of complement turnover and monitoring of complement-targeted therapy, and the assay is widely used in research and clinical monitoring of complement-associated disorders.